RAPAMUNE 1 mg/ml oral solution ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
158	結節性硬化症	2

158. 結節性硬化症

---

臨床試験数 : 112 /  薬物数 : 71 - (DrugBank : 19) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 118

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-004548-64-PL (EUCTR)		08/12/2022	Placebo controlled study to assess the efficacy and safety of rapamycin in drug resistant epilepsy associated with tuberous sclerosis complex	Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of Rapamycin in drug Resistant Epilepsy associated with TSC (RaRE-TS) - RaRE-TS	tuberous sclerosis complex, epilepsy, organ tumors associated with tuberous sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rapamune 1 mg/ml oral solution	The Children's Memorial Health Institute	NULL	NA			Female: yes Male: yes	200	Phase 3	Poland
2	EUCTR2020-003231-19-PL (EUCTR)		09/10/2020	Comparison of the efficacy and safety of rapamycin versus vigabatrin in the prevention of Tuberous Sclerosis Complex symptoms in infants in the randomized clinical trial	Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with Tuberous Sclerosis Complex (ViRap) - ViRap	Tuberous Sclerosis ComplexEpilepsyTumors associated with Tuberous Sclerosis Complex;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: SABRIL 500 mg, granules for oral solution Trade Name: RAPAMUNE 1 mg/ml oral solution	The Children's Memorial Health Institute	NULL	NA			Female: yes Male: yes	60	Phase 2;Phase 3	Poland